Investigations of hydrazine cleavage of eltrombopag in humans

Drug Metabolism and Disposition

Volumn 39, Issue 9, 2011, Pages 1747-1754

  Deng, Yanli ^a   Rogers, Martin ^a   Sychterz, Caroline ^a   Talley, Kimberly ^a   Qian, Yanwen ^a   Bershas, David ^a   Ho, May ^a   Shi, Wei ^a   Chen, Emile P ^a   Serabjit Singh, Cosette ^a   Gorycki, Peter D ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2' HYDROXY 3' AMINO 3 BIPHENYLCARBOXYLIC ACID; BACITRACIN; CYTOCHROME P450; ELTROMBOPAG; HEMOSTATIC AGENT; HYDRAZINE; NEOMYCIN; SB 611855; SODIUM CHLORIDE; STREPTOMYCIN; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ANTIMICROBIAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG CONJUGATION; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG INHIBITION; DRUG STRUCTURE; DRUG URINE LEVEL; FECES HOMOGENATE; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HOMOGENATE; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INHIBITION KINETICS; INTESTINE CONTENT; INTESTINE FLORA; INTESTINE PARAMETERS; KIDNEY MICROSOME; LIVER CELL; LIVER MICROSOME; MALE; MAXIMUM PLASMA CONCENTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; TANDEM MASS SPECTROMETRY; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADMINISTRATION, ORAL; ANIMALS; ANTI-BACTERIAL AGENTS; BENZOIC ACIDS; CECUM; CYTOCHROME P-450 ENZYME SYSTEM; FECES; FEMALE; HEPATOCYTES; HUMANS; HYDRAZINES; KIDNEY; LIVER; MALE; MICE; MICROSOMES; PYRAZOLES; RATS, SPRAGUE-DAWLEY;

MUS; RODENTIA;

EID: 80051997595     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.111.040188     Document Type: Article

References (24)

1. Antila S., Huuskonen H., Nevalainen T., Kanerva H., Vanninen P, and Lehtonen L. (1999) Site dependent bioavailability and metabolism of levosimendan in dogs. Eur J Pharm Sci 9:85-91. (Pubitemid 29430197)
2. Antila S., Pesonen U., Lehtonen L., Tapanainen P., Nikkanen H., Vaahtera K, and Scheinin H. (2004) Pharmacokinetics of levosimendan and its active metabolite OR- 1896 in rapid and slow acetylators. Eur J Pharm Sci 23:213-222. (Pubitemid 39369876)
3. Bjornsson T.D., Callaghan J.T., Einolf H.J., Fischer V., Gan L., Grimm S., Kao J., King S.P., Miwa G., Ni L., et al. (2003) The conduct of in vitro and in vivo drug- Drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective. Drug Metab Dispos 31:815-832. (Pubitemid 36759050)
4. Bussel J.B., Cheng G., Saleh M.N., Psaila B., Kovaleva L., Meddeb B., Kloczko J., Hassani H., Mayer B., Stone N.L., et al. (2007) Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. N Engl J Med 357:2237-2247. (Pubitemid 350190754)
5. Deng Y., Madatian A., Wire M.B., Bowen C., Park J.W., Williams D., Peng B., Schubert E., Gorycki F., Levy M., et al. (2011) Metabolism and disposition of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonist, in healthy human subjects. Drug Metab Dispos 39:1734-1746.
6. Eriksson U.G., Dorani H., Karlsson J., Fritsch H., Hoffmann K.J., Olsson L., Sarich T.C., Wall U, and Schützer K.M. (2006) Influence of erythromycin on the pharmacokinetics of ximelagatran may involve inhibition of P-glycoprotein-mediated excretion. Drug Metab Dispos 34:775-782.
7. Fouda H.G., Avery M.J., Dalvie D., Falkner F.C., Melvin LS, and Ronfeld R.A. (1997) Disposition and metabolism of tenidap in the rat. Drug Metab Dispos 25:140-148. (Pubitemid 27086113)
8. Goldin B.R. (1990) Intestinal microflora: Metabolism of drugs and carcinogens. Ann Med 22:43-48.
9. Greenwood H., Snedden W., Hayward RP, and Landon J. (1975) The measurement of urinary digoxin and dihydrodigoxin by radioimmunoassay and by mass spectroscopy. Clin Chim Acta 62:213-224.
10. Guarner F and Malagelada J.R. (2003) Gut flora in health and disease. Lancet 361:512-519. (Pubitemid 36173720)
11. Ilett K.F., Tee L.B., Reeves PT, and Minchin R.F. (1990) Metabolism of drugs and other xenobiotics in the gut lumen and wall. Pharmacol Ther 46:67-93. (Pubitemid 20067882)
12. Kinouchi T., Kataoka K., Miyanishi K., Akimoto S, and Ohnishi Y. (1993) Biological activities of the intestinal microflora in mice treated with antibiotics or untreated and the effects of the microflora on absorption and metabolic activation of orally administered glutathione conjugates of K- Region epoxides of 1- Region epoxides of 1Nitropyrene. Carcinogenesis 14:869-874. (Pubitemid 23169139)
13. LeBoffe MJ and Pierce B.E. (1996) A Photographic Atlas for the Microbiology Laboratory, p. 7, Morton Publishing Co., Englewood, CO.
14. Lindenbaum J., Rund D.G., Butler V.P. Jr, Tse-Eng D, and Saha J.R. (1981) Inactivation of digoxin by the gut flora: Reversal by antibiotic therapy. N Engl J Med 305:789-794. (Pubitemid 11007233)
15. Mayer U., Wagenaar E., Beijnen J.H., Smit J.W., Meijer D.K., Van Asperen J., Borst P, and Schinkel A.H. (1996) Substantial excretion of digoxin via the intestinal mucosa and prevention of long- Term digoxin accumulation in the brain by the mdr 1a P- Term digoxin accumulation in the brain by the mdr 1a PGlycoprotein. Br J Pharmacol 119:1038-1044. (Pubitemid 26366502)
16. Nicholson J.K., Holmes E, and Wilson I.D. (2005) Gut microorganisms, mammalian metabolism and personalized health care. Nat Rev Microbiol 3:431-438. (Pubitemid 40590386)
17. Rowland I.R. (1986) Reduction by the gut microflora of animals and man. Biochem Pharmacol 35:27-32.
18. Rowland I.R. (1988) Factors affecting metabolic activity of the intestinal microflora. Drug Metab Rev 19:243-261.
19. Saha J.R., Butler V.P. Jr, Neu HC, and Lindenbaum J. (1983) Digoxin- Inactivating bacteria: identification in human gut flora. Science 220:325-327. (Pubitemid 13118491)
20. Scheline R.R. (1973) Metabolism of foreign compounds by gastrointestinal microorganisms. Pharmacol Rev 25:451-523.
21. Smith H.W. (1965) Observations on the flora of the alimentary tract of animals and factors affecting its composition. J Pathol Bacteriol 89:95-122.
22. Sousa T., Paterson R., Moore V., Carlsson A., Abrahamsson B, and Basit A.W. (2008) The gastrointestinal microbiota as a site for the biotransformation of drugs. Int J Pharm 363:1-25.
23. Sweeny D.J., Li W., Clough J., Bhamidipati S., Singh R., Park G., Baluom M., Grossbard E, and Lau D.T. (2010) Metabolism of fostamatinib, the oral methylene phosphate prodrug of the spleen tyrosine kinase inhibitor R406 in humans: Contribution of hepatic and gut bacterial processes to the overall biotransformation. Drug Metab Dispos 38:1166-1176.
24. Williams D.D., Peng B., Bailey C.K., Wire M.B., Deng Y., Park J.W., Collins D.A., Kapsi SG, and Jenkins J.M. (2009) Effects of food and antacids on the pharmacokinetics of eltrombopag in healthy adult subjects: two single-dose, open-label, randomized-sequence, crossover studies. Clin Ther 31:764-776.